<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00303810</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000455572</org_study_id>
    <secondary_id>GPOH-HIT-2000</secondary_id>
    <secondary_id>EU-205105</secondary_id>
    <nct_id>NCT00303810</nct_id>
  </id_info>
  <brief_title>Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma</brief_title>
  <official_title>Multicenter Therapy Optimizing Study for Treatment of Children and Adolescents With Intracranial Medulloblastoma / PNET and Ependymoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in&#xD;
      chemotherapy work in different ways to stop the growth of tumor cells, either by killing the&#xD;
      cells or by stopping them from dividing. Giving radiation therapy in different ways and&#xD;
      giving it together with more than one drug (combination chemotherapy) may kill more tumor&#xD;
      cells. It is not yet known which radiation therapy and combination chemotherapy regimen is&#xD;
      more effective in treating medulloblastoma, supratentorial primitive neuroectodermal tumor&#xD;
      (PNET), or ependymoma.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying six different radiation therapy and combination&#xD;
      chemotherapy regimens to compare how well they work in treating young patients with&#xD;
      medulloblastoma, PNET, or ependymoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare prognosis, using adapted risk stratification and quality control of diagnostic&#xD;
           assessments and therapy, in pediatric patients with intracranial medulloblastoma,&#xD;
           supratentorial primitive neuroectodermal tumor (PNET), or ependymoma treated with&#xD;
           intensified chemotherapy and radiotherapy.&#xD;
&#xD;
        -  Determine the effect of omission of radiotherapy, in terms of long-term sequelae, in&#xD;
           young children with medulloblastoma and by hyperfractionation and reduction of&#xD;
           radiotherapy in older children with medulloblastoma.&#xD;
&#xD;
        -  Compare hyperfractionated radiotherapy with reduced-dose radiotherapy in older children&#xD;
           with stage M0 medulloblastoma.&#xD;
&#xD;
      OUTLINE: This is a multi-protocol study. Patients are enrolled on 1 of 6 treatment protocols&#xD;
      according to diagnosis and age at diagnosis.&#xD;
&#xD;
        -  Protocol HIT-2000-AB4 (≥ 4 years old at diagnosis with nonmetastatic&#xD;
           medulloblastoma)(phase III randomized controlled multicenter study): Patients are&#xD;
           randomized to undergo hyperfractionated radiotherapy or conventional reduced-dose&#xD;
           radiotherapy, followed by vincristine, lomustine, and cisplatin.&#xD;
&#xD;
        -  Protocol HIT-2000-BIS4 (&lt; 4 years old at diagnosis with nonmetastatic medulloblastoma):&#xD;
           Patients receive 5 courses of cyclophosphamide, vincristine, methotrexate, carboplatin,&#xD;
           etoposide phosphate, and intrathecal methotrexate. Patients with residual tumors after 3&#xD;
           courses undergo conventionally fractionated reduced-dose radiotherapy.&#xD;
&#xD;
        -  Protocol MET-HIT-2000-AB4 (≥ 4 years old at diagnosis with metastatic medulloblastoma or&#xD;
           supratentorial PNET): Patients receive combination chemotherapy as in HIT-2000-BIS4 for&#xD;
           2 courses. Patients then undergo hyperfractionated radiotherapy and receive combination&#xD;
           chemotherapy as in HIT-2000-AB4. Patients with good response to combination chemotherapy&#xD;
           (as in HIT-2000-BIS4) also receive high-dose chemotherapy.&#xD;
&#xD;
        -  Protocol MET-HIT-2000-BIS4 (&lt; 4 years old at diagnosis with metastatic medulloblastoma&#xD;
           or supratentorial PNET): Patients receive 2-4 courses of carboplatin IV and etoposide&#xD;
           phosphate IV continuously over 96 hours. Patients with partial or complete response also&#xD;
           receive high-dose carboplatin, etoposide phosphate, cyclophosphamide, and thiotepa.&#xD;
           Patients with residual tumor undergo conventional fractionated, reduced-dose&#xD;
           radiotherapy.&#xD;
&#xD;
        -  Protocol E-HIT-2000-AB4 (≥ 4 years old at diagnosis with intracranial ependymoma):&#xD;
           Patients undergo local hyperfractionated radiotherapy. If histological grading shows WHO&#xD;
           grade III tumor, patients also receive 5 courses of vincristine, cyclophosphamide,&#xD;
           carboplatin, and etoposide phosphate.&#xD;
&#xD;
        -  Protocol E-HIT-2000-BIS4 (&lt; 4 years old at diagnosis with intracranial ependymoma):&#xD;
           Patients receive 5 courses of cyclophosphamide, vincristine, methotrexate IV,&#xD;
           carboplatin, and etoposide phosphate and then undergo conventional fractionated local&#xD;
           radiotherapy.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 567 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2001</start_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">567</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high-dose chemotherapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lomustine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thiotepa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of 1 of the following:&#xD;
&#xD;
               -  Medulloblastoma&#xD;
&#xD;
               -  Supratentorial primitive neuroectodermal tumor (PNET)&#xD;
&#xD;
               -  Ependymoma&#xD;
&#xD;
          -  Intracranial tumor&#xD;
&#xD;
               -  No brain stem tumors&#xD;
&#xD;
          -  No recurrent or relapsed tumors&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Rutkowski, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Med. Center Hamburg, Dpt. of Pediatric Hematology and Oncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frank Deinlein, MD</last_name>
    <affiliation>Universitaets - Kinderklinik Wuerzburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Hamburg - Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>von Bueren AO, von Hoff K, Pietsch T, Gerber NU, Warmuth-Metz M, Deinlein F, Zwiener I, Faldum A, Fleischhack G, Benesch M, Krauss J, Kuehl J, Kortmann RD, Rutkowski S. Treatment of young children with localized medulloblastoma by chemotherapy alone: results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology. Neuro Oncol. 2011 Jun;13(6):669-79. doi: 10.1093/neuonc/nor025.</citation>
    <PMID>21636711</PMID>
  </results_reference>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>March 15, 2006</study_first_submitted>
  <study_first_submitted_qc>March 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2006</study_first_posted>
  <last_update_submitted>January 27, 2014</last_update_submitted>
  <last_update_submitted_qc>January 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2014</last_update_posted>
  <keyword>childhood infratentorial ependymoma</keyword>
  <keyword>childhood supratentorial ependymoma</keyword>
  <keyword>untreated childhood medulloblastoma</keyword>
  <keyword>newly diagnosed childhood ependymoma</keyword>
  <keyword>untreated childhood supratentorial primitive neuroectodermal tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ependymoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Lomustine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

